Rutgeerts PJ[Author] - Search Results

Year	Number of Results
1981	1
1989	1
1993	2
1994	6
1995	2
1996	2
1997	2
1998	4
1999	5
2000	1
2001	3
2004	2
2007	1
2008	1
2009	1
2011	5
2012	2
2013	5
2014	3
2015	1
2016	2
2017	1
2018	1
2019	1
2022	0

1

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. Targan SR, et al. Among authors: rutgeerts pj. N Engl J Med. 1997 Oct 9;337(15):1029-35. doi: 10.1056/NEJM199710093371502. N Engl J Med. 1997. PMID: 9321530 Free article. Clinical Trial.

2

Drug safety evaluation of certolizumab pegol.

Ferrante M, Vermeire S, Rutgeerts PJ. Ferrante M, et al. Among authors: rutgeerts pj. Expert Opin Drug Saf. 2014 Feb;13(2):255-66. doi: 10.1517/14740338.2014.851666. Epub 2013 Oct 25. Expert Opin Drug Saf. 2014. PMID: 24156537 Review.

3

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.

D'Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Schölmerich J, Hanauer S, Sandborn WJ; IOIBD Membership. D'Haens GR, et al. Among authors: rutgeerts pj. Inflamm Bowel Dis. 2009 Oct;15(10):1599-604. doi: 10.1002/ibd.21034. Inflamm Bowel Dis. 2009. PMID: 19653291 Review.

4

Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience.

Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Danese S, et al. Among authors: rutgeerts pj. Aliment Pharmacol Ther. 2011 Apr;33(8):857-69. doi: 10.1111/j.1365-2036.2011.04598.x. Epub 2011 Feb 15. Aliment Pharmacol Ther. 2011. PMID: 21320139 Free article. Review.

5

Conventional treatment of Crohn's disease: objectives and outcomes.

Rutgeerts PJ. Rutgeerts PJ. Inflamm Bowel Dis. 2001 May;7 Suppl 1:S2-8. doi: 10.1002/ibd.3780070503. Inflamm Bowel Dis. 2001. PMID: 11380039 Review.

6

Medical therapies for ulcerative colitis and Crohn's disease.

Baert FJ, Rutgeerts PJ. Baert FJ, et al. Among authors: rutgeerts pj. Curr Gastroenterol Rep. 2000 Dec;2(6):446-50. doi: 10.1007/s11894-000-0006-z. Curr Gastroenterol Rep. 2000. PMID: 11079045 Review.

7

An historical overview of the treatment of Crohn's disease: why do we need biological therapies?

Rutgeerts PJ. Rutgeerts PJ. Rev Gastroenterol Disord. 2004;4 Suppl 3:S3-9. Rev Gastroenterol Disord. 2004. PMID: 15580150 Review.

8

Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.

Rutgeerts PJ. Rutgeerts PJ. Aliment Pharmacol Ther. 1999 Sep;13 Suppl 4:9-15; discussion 38. doi: 10.1046/j.1365-2036.1999.00025.x. Aliment Pharmacol Ther. 1999. PMID: 10597334 Free article. Review.

9

Review article: the limitations of corticosteroid therapy in Crohn's disease.

Rutgeerts PJ. Rutgeerts PJ. Aliment Pharmacol Ther. 2001 Oct;15(10):1515-25. doi: 10.1046/j.1365-2036.2001.01060.x. Aliment Pharmacol Ther. 2001. PMID: 11563990 Free article. Review.

10

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.

Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. Colombel JF, et al. Among authors: rutgeerts pj. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1525-1532.e1. doi: 10.1016/j.cgh.2018.09.033. Epub 2018 Sep 26. Clin Gastroenterol Hepatol. 2019. PMID: 30267864 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results